Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): A French interdisciplinary therapeutic algorithm

Supportive Care in Cancer

Volumn 20, Issue 7, 2012, Pages 1395-1404

  Reguiai, Z ^a   Bachet, J B ^b   Bachmeyer, C ^b   Peuvrel, L ^c   Beylot Barry, M ^d   Bezier, M ^e   Boucher, E ^f   Chevelle, C ^g   Colin, P ^h   Guimbaud, R ⁱ   Mineur, L ^j   Richard, M A ^k   Artru, P ^l   Dufour, P ^m   Gornet, J M ^e   Samalin, E ⁿ   Bensadoun, R J ^o   Ychou, M ⁿ   Andre T ^p   Dreno, B ^c   Bouche O ^q   more..

^a SERVICE DE DERMATOLOGIE   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔTEL DIEU   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f CENTRE EUGÈNE MARQUIS   (France)

^g CLINIQUE PASTEUR   (France)

^h Clinique Pasteur ^*  (France)

ⁱ CHU RANGUEIL   (France)

^j INSTITUT SAINTE CATHERINE   (France)

^k TIMONE HOSPITAL   (France)

^l Department of Internal Medicine Oncology   (France)

^m CENTRE PAUL STRAUSS   (France)

ⁿ CENTRE VAL D AURELLE   (France)

^o POITIERS UNIVERSITY HOSPITAL   (France)

^p HÔPITAL SAINT ANTOINE   (France)

^q REIMS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Cetuximab; Drug eruption; Epidermal growth factor receptor inhibitors; Erlotinib; Gefitinib; Panitumumab; Paronychia; Pruritus

Indexed keywords

ANTIBIOTIC AGENT; APREPITANT; CETUXIMAB; CORTICOSTEROID; DOXYCYCLINE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROCORTISONE; LYMECYCLINE; MINOCYCLINE; PANITUMUMAB; PIMECROLIMUS; SILVER NITRATE; STEROID; TAZAROTENE; TETRACYCLINE;

ALGORITHM; ALOPECIA; CARBON DIOXIDE LASER; CONTINUOUS INFUSION; DRUG WITHDRAWAL; ELECTROCOAGULATION; EVENING DOSAGE; FOLLICULITIS; FRANCE; HAIR DISEASE; HEALTH CARE MANAGEMENT; HIRSUTISM; HUMAN; HYPERTRICHOSIS; METHODOLOGY; PARONYCHIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; PYOGENIC GRANULOMA; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN INFECTION; SKIN PROTECTION; SKIN TOXICITY; SYSTEMATIC REVIEW; TRICHOMEGALY; XEROSIS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FOLLICULITIS; FRANCE; HUMANS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TETRACYCLINES;

EID: 84863982274     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1451-6     Document Type: Review

References (32)

1. Segaert S, Tabernero J, Chosidow O et al (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3:599-606
2. Segaert S, Van Cutsem E (2007) Clinical management of EGFRI dermatologic toxicities: the European perspective. Oncology (Williston Park) 21:S22-S26
3. Melosky B, Burkes R, Rayson D et al (2009) Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 16:14-24
4. Eaby B, Culkin A, Lacouture ME (2008) An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs 12:283-290
5. Lacouture ME, Maitland ML, Segaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509-522
6. Lacouture ME, Cotliar J, Mitchell EP (2007) Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park) 21(11 Suppl 5):17-21
7. Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079-1095
8. Duvic M (2008) EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol 9:285-294
9. Bernier J, Bonner J, Vermoken JB et al (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19:142-149
10. Fox LP (2006) Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology (Williston Park) 20:26-34
11. Gridelli C, Maione P, Amoroso D et al (2008) Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Hematol 66:156-162
12. Hu JC, Sadeghi P, Pinter-Brown LC et al (2007) Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56:317-326
13. Potthoff K, Hofheinz R, Hassel JC et al (2011) Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 22:524-535
14. Oishi KJ, Garey JS, Burke BJ et al (2006) Managing cutaneous side effects associated with erlotinib in head and neck cancer and non small lung cancer patient. J Clin Oncol 24:18s (abstract 18538)
15. Bouché O, Scaglia E, Reguiaï Z et al (2009) Biothérapies ciblées en cancérologie digestive: prise en charge de leurs effets secondaires. Gastroenterol Clin Biol 33:306-322
16. van Tulder M, Furlan A, Bombardier C et al (2003) Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 28:1290-1299
17. CEBM-http://www.cebm.net/index.aspx?o01025
18. Lacouture ME, Mitchell EP, Piperdi B et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, openlabel, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351-1357
19. Jatoi A, Rowland K, Sloan JA et al (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 13:847-853
20. Deplanque G, Chavaillon J, Vergnenegre A et al (2010) CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 28(No 15-suppl):A9019
21. Scope A, Agero AL, Dusza SW et al (2007) Randomized doubleblind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390-5396
22. Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921
23. Matheis P, Socinski MA, Burkhart C et al (2006) Treatment of gefitinib-associated folliculitis. J Am Acad Dermatol 55:710-713
24. Molinari E, De Quatrebarbes J, André T et al (2005) Cetuximabinduced acne. Dermatology 211:330-333
25. de Noronha e Menezes NM, Lima R et al (2009) Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol 19:248-251
26. Scope A, Lieb JA, Dusza SW et al (2009) A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61:614-620
27. Amitay-Laish I, David M, Stemmer SM (2010) Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 15:1002-1008
28. Vergou T, Stratigos AJ, Karapanagiotou EM et al (2010) Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol 63:e56-e58
29. Bouché O, Brixi-Benmansour H, Bertin A et al (2005) Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 16:1711-1712
30. Vincenzi B, Tonini G, Santini D (2010) Aprepitant for erlotinibinduced pruritus. N Engl J Med 363:397-398
31. NCI Common Terminology Criteria for Adverse Events (CTCAE) v4. ctep.cancer.gov/reporting/ctc.html
32. Boone SL, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152-159